Peptide Initiative

Peptides · Peptide comparison

Lactoferricin B vs Thymosin Alpha-1

A 25-amino-acid antimicrobial peptide fragment derived from bovine lactoferrin by pepsin cleavage, featuring a twisted antiparallel beta-sheet structure with broad-spectrum bactericidal activity, anti-biofilm properties, and emerging anticancer potential through selective membrane disruption mediated by the critical RRWQWR motif

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeLactoferricin B1–10 mgThymosin Alpha-11.6–1.6 mg
FrequencyLactoferricin BMultiple times dailyThymosin Alpha-1Twice weekly
AdministrationLactoferricin BOral (research — resistant to gastric digestion)Thymosin Alpha-1Subcutaneous injection
Cycle lengthLactoferricin B4-6 weeksThymosin Alpha-18-12 weeks
Onset speedLactoferricin BRapid (hours to days)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelLactoferricin BModerate human trials (Phase 1-2)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Fighting Germs

Lactoferricin B94%
Thymosin Alpha-1No recorded rating

Cancer Cell Targeting

Lactoferricin B86%
Thymosin Alpha-1No recorded rating

Immune Support

Lactoferricin B82%
Thymosin Alpha-1No recorded rating

Immune Activation

Lactoferricin BNo recorded rating
Thymosin Alpha-195%

Infection Fighting

Lactoferricin BNo recorded rating
Thymosin Alpha-192%

Immune Balance

Lactoferricin BNo recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Lactoferricin B

Molecular formula
Approximately C142H224N46O34S2 (varies slightly by reported sequence)
Molecular weight
~3,126 Da (25-amino-acid bovine lactoferricin B)
Half-life
Plasma half-life: minutes (proteolytic degradation); gastrointestinal persistence: hours (relative resistance to trypsin and chymotrypsin compared to unstructured peptides); beta-sheet structure and disulfide bond provide moderate protease resistance
Bioavailability
Generated endogenously during gastric digestion of dietary lactoferrin; partially resistant to further proteolytic degradation due to beta-sheet structure and disulfide bond; systemic bioavailability limited by intestinal proteases and hepatic metabolism
CAS number
146897-68-9

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Lactoferricin B

No dose levels recorded.

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Lactoferricin B

Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
Lactoferricin B is particularly well-suited for individuals focused on research into dairy-derived antimicrobial peptides and natural innate defense mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
Lactoferricin B is particularly well-suited for individuals focused on investigation of structure-activity relationships in beta-sheet antimicrobial peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
Lactoferricin B is particularly well-suited for individuals focused on preclinical development of anticancer peptides targeting membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
Lactoferricin B is particularly well-suited for individuals focused on understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Lactoferricin B

Common

  • Mild GI discomfort
  • Bitter taste
  • Local irritation (topical use)
  • Mild flatulence

Uncommon

  • Allergic reaction in milk-sensitive individuals

Serious

  • Hemolytic activity at high concentrations

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Lactoferricin B

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Lactoferricin B is a 25-amino acid peptide fragment of bovine lactoferrin, a protein found in cow's milk [2]. Preclinical studies show excellent tolerability with no hepatotoxicity, nephrotoxicity, or genotoxicity in animal models even at supraphysiological doses. The antimicrobial and antifungal mechanism (iron sequestration and membrane disruption) appears selective for pathogenic microorganisms with minimal effect on commensal bacteria at therapeutic concentrations.

Contraindications

  • Known allergy to bovine milk proteins or lactoferrin — cross-reactivity possible
  • Pregnancy and breastfeeding — insufficient safety data for therapeutic-dose lactoferricin supplementation
  • Active hemolytic conditions — at higher concentrations lactoferricin shows some hemolytic activity that may worsen hemolysis
  • Iron overload conditions (hemochromatosis) — lactoferricin retains some iron-binding capacity from the parent lactoferrin molecule

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Lactoferricin B

Choose Lactoferricin B if…

  • Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
  • Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
  • Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
  • Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support